NextPlat 2026 nine-month revenue falls 21% to $32.2M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
NextPlat Corp (NXPL) reported revenue of $32.235 million for the nine months ended September 30, 2026, down 21% from $40.918 million in the comparable 2025 period. Net loss narrowed to $2.024 million from $5.916 million; gross profit rose to $11.784 million from $8.477 million, and operating cash use was $2.065 million versus $5.828 million.
Healthcare prescription revenue fell while pharmacy contract revenue increased. On October 30, Oscar-plan claims were suspended at PharmcoRx’s Hallandale Beach location until Oscar’s investigation is resolved or further notice; NextPlat expects revenue to decline about $0.3 million monthly during the suspension. NextPlat completed a $1.5 million cash acquisition of Scott’s Pharmacy on October 1.
Management concluded its plans alleviate substantial doubt about going concern. As of September 30, 2026, NextPlat maintained a $1.75 million accrual for a putative class action concerning October 2024 merger consideration, brought by former Progressive Care Inc. Chief Executive Officer and Chairman Alan Jay Weisberg against NextPlat, former NextPlat Chief Executive Officer and Executive Chairman Charles M. Fernandez, and NextPlat director Rodney Barreto. The court denied a motion to dismiss on December 3, 2025; class-certification argument is scheduled for January 7, 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNet loss narrowed 66% to $2.024 million for the nine months.
- Moderate pointOperating cash use fell to $2.065 million from $5.828 million.
Negative
- Moderate pointNine-month revenue fell 21% to $32.235 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Oscar-plan suspension is expected to reduce revenue by about $0.3 million monthly.
Filing Explained
At September thirtieth, Oscar claims had two and a half million dollars in receivables and two million payable; no recoupment was asserted.
The 10-Q reports that NextPlat began ATM sales on
An at-the-market program allows gradual sales of new shares at prevailing prices; if issued, those shares increase the total share count and reduce existing holders’ percentage ownership.
For Oscar-plan claims at PharmcoRx’s Hallandale Beach location, the filing reports
Under the agreements, covered entities are responsible for recoupments on 340B drugs, less PharmcoRx’s dispensing fees, while PharmcoRx bears the risk that a covered entity does not pay; because Oscar has not identified claims, the possible loss cannot currently be estimated.
Key Figures
Key Terms
at-the-market offering financial
going concern financial
340B Drug Discount Pricing Program regulatory
adjudication suspension medical
right-of-use asset technical
business combination financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did NXPL perform in the nine months ended September 30, 2026?
How much could the Oscar-plan suspension reduce NXPL revenue?
What are the terms of NXPL’s ATM program?
What did NXPL pay for Scott’s Pharmacy?
Why did NXPL discuss substantial doubt about its ability to continue as a going concern?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
| | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT |
For the transition period from ______________to _______________.
Commission File Number
NEXTPLAT CORP
(Exact name of registrant as specified in its charter)
| | | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
| | | |
| (Address of principal executive offices) | (Zip Code) |
(
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| | | The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| | Smaller reporting company |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes
Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.
| Class | Outstanding at November 9, 2026 | |
| Common Stock, $0.0001 par value | |
FORM 10-Q
INDEX
| Page |
|
| PART I. FINANCIAL INFORMATION |
|
| ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) |
2 |
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS |
2 |
| CONDENSED CONSOLIDATED BALANCE SHEETS | 3 |
| CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY |
4 |
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
5 |
| NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS |
6 |
| ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
24 |
| ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
34 |
| ITEM 4. CONTROLS AND PROCEDURES |
35 |
| PART II. OTHER INFORMATION |
|
| ITEM 1. LEGAL PROCEEDINGS |
36 |
| ITEM 1A. RISK FACTORS | 37 |
| ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
38 |
| ITEM 3. DEFAULTS UPON SENIOR SECURITIES | 38 |
| ITEM 4. MINE SAFETY DISCLOSURES | 38 |
| ITEM 5. OTHER INFORMATION |
38 |
| ITEM 6. EXHIBITS |
39 |
| SIGNATURES |
40 |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This quarterly report and other documents that we file with the Securities and Exchange Commission (“SEC”) contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management’s assumptions. Statements that are not historical facts are forward-looking statements, including forward-looking information concerning sales trends, gross margins, number and location of new store openings, outcomes of litigation, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, acquisition synergies, regulatory approvals, and competitive strengths. Words such as “expect,” “outlook,” “forecast,” “would,” “could,” “should,” “project,” “intend,” “plan,” “continue,” “sustain,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “assume,” and variations of such words and similar expressions are often used to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, those described in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026 (“2025 Form 10-K”), this quarterly report on Form 10-Q for the three and nine months ended September 30, 2026, and our other reports that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after the date they are made, whether as a result of new information, future events, changes in assumptions or otherwise.
PART I. FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
The accompanying Condensed Consolidated Financial Statements of NextPlat Corp (“NextPlat,” the “Company,” “we,” or “our”), for the three and nine months ended September 30, 2026 and for the comparable period in the prior year are included below. These Condensed Consolidated Financial Statements should be read in conjunction with the Notes to the Condensed Consolidated Financial Statements that follow.
NEXTPLAT CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share data)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues, net | $ | $ | $ | $ | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Salaries, wages and payroll taxes | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Intangible asset amortization | ||||||||||||||||
| Loss on settlement of litigation | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Non-operating (income) expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income taxes benefit (expense) | ( | ) | ( | ) | ||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss attributable to non-controlling interest | ||||||||||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Foreign currency (loss) gain | ( | ) | ( | ) | ||||||||||||
| Comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of common shares outstanding – basic and diluted | ||||||||||||||||
| Basic and diluted loss per share | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
See accompanying notes to condensed consolidated financial statements.
NEXTPLAT CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except shares and par value data)
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | (Audited) | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | $ | $ | ||||||
| Receivables, net of allowances of $64 and $40 as of September 30, 2026 and December 31, 2025, respectively | ||||||||
| Inventory, net of inventory reserves of $416 and $418 as of September 30, 2026 and December 31, 2025, respectively | ||||||||
| Other current assets | ||||||||
| Total Current Assets | ||||||||
| Property and equipment, net of accumulated depreciation of $948 and $3,527 as of September 30, 2026 and December 31, 2025, respectively | ||||||||
| Operating right-of-use assets, net | ||||||||
| Goodwill | ||||||||
| Intangible assets, net | ||||||||
| Other noncurrent assets | ||||||||
| Total Assets | $ | $ | ||||||
| LIABILITIES AND EQUITY | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Notes payable | ||||||||
| Operating lease liabilities | ||||||||
| Other current liabilities | ||||||||
| Total Current Liabilities | ||||||||
| Long Term Liabilities: | ||||||||
| Notes payable, net of current portion | ||||||||
| Operating lease liabilities, net of current portion | ||||||||
| Total Liabilities | ||||||||
| Commitments and Contingencies | — | — | ||||||
| Equity | ||||||||
| Preferred stock ($0.0001 par value; 3,333,333 shares authorized; no shares issued or outstanding) | — | — | ||||||
| Common stock ($0.0001 par value; 50,000,000 shares authorized, 2,721,529 and 2,676,788 shares issued and 2,708,475 and 2,663,734 shares outstanding as of September 30, 2026 and December 31, 2025, respectively) | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Treasury stock (at cost; 13,054 shares as of September 30, 2026 and December 31, 2025) | ( | ) | ( | ) | ||||
| Equity attributable to common stockholders | ||||||||
| Equity attributable to non-controlling interests | ||||||||
| Total Equity | ||||||||
| Total Liabilities and Equity | $ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
NEXTPLAT CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In thousands, except par value)
(Unaudited)
For the Three and Nine Months Ended September 30, 2026
| Common Stock | Additional | Treasury Stock | ||||||||||||||||||||||||||||||||||||||
| $0.0001 Par Value | Paid in | Accumulated | Comprehensive | Cost | Stockholders’ | Non-controlling | Total | |||||||||||||||||||||||||||||||||
| Shares | Amount | Capital | Deficit | Loss | Shares | Amount | Equity | Interests | Equity | |||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||
| Issuance of common stock related to restricted stock award | ||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation in connection with restricted stock awards | — | — | ||||||||||||||||||||||||||||||||||||||
| Comprehensive gain | — | — | ||||||||||||||||||||||||||||||||||||||
| Net loss | — | ( | ) | — | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Stock-based compensation in connection with restricted stock awards | 10 | — | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock related to restricted stock award | ||||||||||||||||||||||||||||||||||||||||
| Cancellation of common stock related to reverse stock split | — | ( | ) | — | — | |||||||||||||||||||||||||||||||||||
| Comprehensive loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Net loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Stock-based compensation in connection with restricted stock awards | 3 | — | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock related to restricted stock award | ||||||||||||||||||||||||||||||||||||||||
| Comprehensive loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Net loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||
For the Three and Nine Months Ended September 30, 2025
| Common Stock | Additional | Treasury Stock | ||||||||||||||||||||||||||||||||||||||
| $0.0001 Par Value | Paid in | Accumulated | Comprehensive | Cost | Stockholders’ | Non-controlling | Total | |||||||||||||||||||||||||||||||||
| Shares | Amount | Capital | Deficit | Loss | Shares | Amount | Equity | Interests | Equity | |||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | $ | ||||||||||||||||||||||||||||
| Stock-based compensation in connection with options granted | — | — | ||||||||||||||||||||||||||||||||||||||
| Comprehensive loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Net loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation in connection with options granted | — | — | ||||||||||||||||||||||||||||||||||||||
| Comprehensive loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Net loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Issuance of common stock related to restricted stock award | ||||||||||||||||||||||||||||||||||||||||
| Shares repurchased | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Comprehensive gain | — | — | ||||||||||||||||||||||||||||||||||||||
| Net loss | — | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||
See accompanying notes to condensed consolidated financial statements.
NEXTPLAT CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Cash received from e-Commerce Operations revenue | $ | $ | ||||||
| Cash received from Healthcare Operations revenue | ||||||||
| Cash received from interest income | ||||||||
| Cash (paid) received from other sources | ( | ) | ||||||
| Cash paid for inventory purchases and other costs of revenue | ( | ) | ( | ) | ||||
| Cash paid for salaries and related expenses | ( | ) | ( | ) | ||||
| Cash paid for other recurring operating expenses | ( | ) | ( | ) | ||||
| Cash paid for other non-recurring expenses | ( | ) | ( | ) | ||||
| Cash paid for interest expense | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of property and equipment | ( | ) | ( | ) | ||||
| Proceeds from sale of property and equipment | ||||||||
| Net cash (used in) provided by investing activities | ( | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Repayments of notes payable | ( | ) | ( | ) | ||||
| Payments on finance lease liabilities | ( | ) | ||||||
| Acquisition of issued common stock held in treasury | ( | ) | ||||||
| Net cash used in financing activities | ( | ) | ( | ) | ||||
| Effect of exchange rate on cash | ( | ) | ||||||
| Net decrease in cash | ( | ) | ( | ) | ||||
| Cash beginning of period | ||||||||
| Cash end of period | $ | $ | ||||||
| Reconciliation of net loss to cash flow used in operating activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | ||||||||
| Change in allowance for credit losses | ( | ) | ||||||
| Change in inventory reserve | ( | ) | ||||||
| Amortization of intangible assets | ||||||||
| Amortization of operating right-of-use assets | ||||||||
| Amortization of finance right-of-use assets | ||||||||
| Stock-based compensation | ||||||||
| Loss on sale of property and equipment | ||||||||
| Change in operating assets and liabilities: | ||||||||
| Receivables | ( | ) | ||||||
| Inventories | ( | ) | ( | ) | ||||
| Other current assets | ||||||||
| Other noncurrent assets | ( | ) | ||||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Other current liabilities | ||||||||
| Net cash used in operating activities | $ | ( | ) | $ | ( | ) | ||
| Supplemental disclosures of noncash activities: | ||||||||
| Right-of-use assets obtained in exchange for operating lease liabilities from new leases and lease modifications | ||||||||
See accompanying notes to condensed consolidated financial statements.
Note 1. Organization and Nature of Operations
NextPlat Corp is a Nevada corporation (the “Company”, “NextPlat”, “we”) reporting on the Nasdaq Capital Market exchange that has business segments operating in the e-Commerce and Healthcare sectors. It was incorporated in 1997 with executive offices located in Hallandale Beach, Florida.
e-Commerce Operations:
The Company operates three main e-Commerce websites as well as 25 third-party e-Commerce storefronts on platforms such as Alibaba, Amazon, Decathlon, Mercado Libre, Mountain Warehouse, and Walmart. These e-Commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Additionally, we provide a comprehensive array of satellite-enabled communication services and related equipment sales.
The Company’s wholly owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. GTC provides e-Commerce and satellite-enabled communication services on a global basis.
The Company’s wholly owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014. Orbital Satcom provides e-Commerce and satellite-enabled communication services to customers in the U.S.
The Company’s wholly owned subsidiary, Outfitter Satellite, Inc., a Tennessee corporation (“Outfitter”), was acquired in April 2024 in a stock purchase transaction. Outfitter provides consumers, commercial and government customers with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar.
Florida Sunshine Brands, LLC:
Florida Sunshine Brands, LLC (“Florida Sunshine”) is a Florida limited liability company formed on December 6, 2023. Florida Sunshine operates under an operating agreement between NextPlat, with a
Healthcare Operations:
The Company’s Healthcare segment operates through a wholly owned entity, Progressive Care LLC (“Progressive”), a Nevada Limited Liability Company, which includes wholly owned subsidiaries, Pharmco, LLC (“Pharmco 901”), Touchpoint RX, LLC doing business as Pharmco Rx 1002, LLC (“Pharmco 1002”), Family Physicians RX, Inc. doing business as PharmcoRx 1103 and PharmcoRx 1204 (“FPRX” or “Pharmco 1103” and “Pharmco 1204”) (pharmacy subsidiaries collectively referred to as “Pharmco”), and ClearMetrX Inc. (“ClearMetrX”). ClearMetrX is a personalized healthcare services and technology company that provides prescription pharmaceuticals and risk and data management services to healthcare organizations and providers. Pharmco pharmacies deliver prescriptions to Florida’s diverse population and currently hold Florida Community Pharmacy Permits at all Florida pharmacy locations.
Pharmco 901 is a pharmacy located in Hallandale Beach, Florida, and is licensed as a non-resident pharmacy in the following states: Arizona, Colorado, Connecticut, Georgia, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah.
Pharmco 1002 is a pharmacy located in Palm Springs, Florida that provides pharmacy services to Palm Beach, St. Lucie and Martin Counties, Florida.
FPRX is a pharmacy with locations in North Miami Beach and Orlando, Florida that provides pharmacy services to Miami-Dade County, Broward County, the Orlando/Tampa corridor, and the Treasure Coast of Florida.
ClearMetrX was formed on June 10, 2020 and provides third-party administration (“TPA”) services to 340B covered entities. ClearMetrX also provides data analytics and reporting services to support and improve care management for health care organizations.
RXMD Therapeutics was formed on October 1, 2019. RXMD Therapeutics has had no operating activity to date.
Note 2. Basis of Presentation and Principles of Consolidation
The accompanying Condensed Consolidated Financial Statements of the Company are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), consistent in all material respects with those applied in the 2025 Annual Report on Form 10-K, for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2025 Form 10-K. In the opinion of management, the Condensed Consolidated Financial Statements contain all adjustments (consisting principally of normal recurring accruals) necessary for a fair presentation of the condensed consolidated statements of comprehensive loss, balance sheets, statements of equity, and statements of cash flows for such interim periods presented. Additionally, operating results for interim periods are not necessarily indicative of the results that can be expected for a full year. The year-end balance sheet data for comparative purposes was derived from audited consolidated financial statements.
The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.
Reclassifications
Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Professional fees are included in selling, general and administrative and approximately $
Correction of Immaterial Misstatement
As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Company recorded an adjustment to correct an error related to performance bonus revenue in the amount of approximately $
Reverse Stock Split
On April 13, 2026, the Company effected a 1-for-
Use of Estimates
In preparing the Condensed Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the periods then ended. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, assumptions used to calculate stock-based compensation, fair value of net assets acquired in business combinations, valuation of common stock warrants and options issued for services, net realizable value and credit loss reserves of accounts receivables and other receivables, the useful lives of property and equipment and intangible assets, assumptions used in determining the potential impairment of long-lived assets, including intangible assets and goodwill, the estimate of the fair value of the lease liability and related right-of-use assets, inventory reserve estimates, and the estimates of the valuation allowance on deferred tax assets and corporate income taxes.
Note 3. Summary of Significant Accounting Policies
The significant accounting policies of the Company were described in Note 3 to the Audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Other than the following, there have been no material changes to the Company’s significant accounting policies for the nine months ended September 30, 2026. Selected accounting policy disclosures are provided below.
Cash
The Company places its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $
Foreign Currency Translation
The Company’s reporting currency is U.S. Dollars. The accounts of one of the Company’s subsidiaries, GTC, are maintained using the appropriate local currency, British Pound (“GBP”), as the functional currency. All assets and liabilities are translated into U.S. Dollars at the balance sheet date, shareholders’ equity is translated at historical rates and revenue and expense accounts are translated at the average exchange rate for the year or the reporting period. The translation adjustments are reported as a separate component of stockholders’ equity, captioned as accumulated other comprehensive (loss) gain. Transaction gains and losses arising from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the Condensed Consolidated Statements of Comprehensive Loss.
The relevant translation rates are as follows:
| As of September 30, 2026 | As of September 30, 2025 | As of December 31, 2025 | ||||||||||
| Closing rate (U.S. dollars per British pound) | $ | $ | $ | |||||||||
| Quarterly average rate (U.S. dollars per British pound) | $ | $ | $ | |||||||||
| Year-to-date average rate (U.S. dollars per British pound) | $ | $ | $ | |||||||||
Recent Accounting Pronouncements and Income Tax Legislation
Accounting Pronouncements Recently Adopted
In December 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2025-12, “Codification Improvements,” which includes numerous amendments across a broad range of Topics to clarify existing guidance, correct errors, and otherwise improve the usability and consistency of the Accounting Standards Codification. Key areas addressed include clarifications to the diluted earnings per share calculation when a loss from continuing operations exists, clarification of disclosure requirements for lease receivables arising from certain leases, revisions to the reference amount for beneficial interests, and other technical improvements. ASU 2025-12 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company early adopted ASU 2025-12 effective January 1, 2026. The amendments to Topic 260, Earnings per Share, were applied retrospectively to all periods presented, as required, and all other amendments were applied prospectively. The adoption did not have a material impact on the Company’s condensed consolidated financial statements.
Accounting Pronouncements Issued but not yet Adopted
In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements,” which is intended to clarify and improve the guidance in Topic 270, Interim Reporting. The amendments clarify the applicability of interim reporting guidance, the types of interim reporting, the form and content of interim financial statements and notes prepared in accordance with U.S. GAAP, and establish a principle for disclosing events and changes since the end of the last annual reporting period that have a material impact on the entity. The amendments are not intended to change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities, with early adoption permitted. The Company has not yet adopted ASU 2025-11 and does not expect the adoption of this ASU to have a material impact on its condensed consolidated financial statements.
Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to be relevant or have a material impact on the condensed consolidated financial statements upon adoption.
Note 4. Liquidity, Going Concern, and Management’s Plans
The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring operating losses and historically generated negative operating cash flows. These conditions raised substantial doubt about the Company’s ability to continue as a going concern for the twelve months following the issuance of these Condensed Consolidated Financial Statements.
Management has evaluated its plans to mitigate these conditions. These plans include expanding the Company’s long-term care pharmacy operations, increasing 340B contract pharmacy revenue, developing additional institutional medication fulfillment contracts, implementing identified operational efficiencies, and utilizing the ATM Program. Management also considered the adjudication suspension imposed on October 30, 2026 on PharmcoRx's Hallandale Beach, Florida location for claims adjudicated to Oscar Health plans. For the nine months ended September 30, 2026, revenue from these claims was approximately $
Note 5. Revenue
The following tables disaggregate net revenues by major categories (in thousands):
| Three Months Ended September 30, 2026 | ||||||||||||
| e-Commerce Operations | Healthcare Operations | Total | ||||||||||
| e-Commerce revenue | $ | $ | $ | |||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||
| Pharmacy contract revenue | ||||||||||||
| Revenues, net | $ | $ | $ | |||||||||
| Three Months Ended September 30, 2025 | ||||||||||||
| e-Commerce Operations | Healthcare Operations | Total | ||||||||||
| e-Commerce revenue | $ | $ | $ | |||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||
| Pharmacy contract revenue | ||||||||||||
| Revenues, net | $ | $ | $ | |||||||||
| Nine Months Ended September 30, 2026 | ||||||||||||
| e-Commerce Operations | Healthcare Operations | Total | ||||||||||
| e-Commerce revenue | $ | $ | $ | |||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||
| Pharmacy contract revenue | ||||||||||||
| Revenues, net | $ | $ | $ | |||||||||
| Nine Months Ended September 30, 2025 | ||||||||||||
| e-Commerce Operations | Healthcare Operations | Total | ||||||||||
| e-Commerce revenue | $ | $ | $ | |||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||
| Pharmacy contract revenue | ||||||||||||
| Revenues, net | $ | $ | $ | |||||||||
Note 6. Earnings (Loss) per Share
Net income (loss) per common share is calculated in accordance with ASC Topic 260: Earnings per Share (“ASC 260”). Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding as they would be anti-dilutive. All share and per-share amounts, including weighted average shares outstanding used to compute basic and diluted loss per share, have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.
The components of basic and diluted EPS were as follows (in thousands, except per share data). For all periods presented, the Company incurred a net loss causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in diluted loss per common share and basic loss per common share being equivalent. In addition, the exercise prices of all outstanding stock options and warrants exceeded the average market price of the Company’s common stock in each period presented.
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic weighted average common shares outstanding | ||||||||||||||||
| Potentially dilutive common shares | ||||||||||||||||
| Diluted weighted average common shares outstanding | ||||||||||||||||
| Weighted average loss per common share - basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: | ||||||||||||||||
| Unvested restricted stock awards | ||||||||||||||||
| Stock options | ||||||||||||||||
| Common stock purchase warrants | ||||||||||||||||
Note 7. Receivables, net
Receivables, net consisted of the following (in thousands):
| September 30, 2026 | December 31, 2025 | |||||||
| Gross accounts receivable – trade | $ | $ | ||||||
| Performance bonuses | ||||||||
| Customers | ||||||||
| Other | ||||||||
| Subtotal | ||||||||
| Less: allowance for credit losses | ( | ) | ( | ) | ||||
| Receivables, net | $ | $ | ||||||
Note 8. Inventory, net
Inventory, net consisted of the following (in thousands):
| September 30, 2026 | December 31, 2025 | |||||||
| Finished goods | $ | $ | ||||||
| Less inventory reserve | ( | ) | ( | ) | ||||
| Inventory, net | $ | $ | ||||||
Note 9. Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consisted of the following (in thousands):
| September 30, 2026 | December 31, 2025 | |||||||
| Accounts payable | $ | $ | ||||||
| Accrued litigation | ||||||||
| Accrued wages and payroll liabilities | ||||||||
| Accrued other liabilities | ||||||||
| Customer deposits payable | ||||||||
| Total | $ | $ | ||||||
Note 10. Notes Payable
Notes payable consisted of the following (in thousands):
| September 30, 2026 | December 31, 2025 | |||||||
| A. Mortgage note payable - commercial bank - collateralized | $ | $ | ||||||
| B. Note payable - uncollateralized | ||||||||
| C. Notes payable - collateralized | ||||||||
| Insurance premiums financing | ||||||||
| Subtotal | ||||||||
| Less: current portion of notes payable | ( | ) | ( | ) | ||||
| Long-term portion of notes payable | $ | $ | ||||||
(A) Mortgage Note Payable – collateralized
In 2018, Pharmco closed on the purchase of land and building located at 400 Ansin Boulevard, Hallandale Beach, Florida. The purchase price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of $
(B) Note Payable – Uncollateralized
As of September 30, 2026 the uncollateralized note payable represents a non-interest-bearing loan that is due on demand from an investor.
(C) Notes Payable – Collateralized
On July 16, 2020 (the “Issue Date”), GTC entered into a Coronavirus Interruption Loan Agreement (“Debenture”) by and among the Company and HSBC UK Bank PLC (the “Lender”) for an amount of approximately £0.3 million, or USD $
In July 2022, Progressive Care entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $
Principal outstanding as of September 30, 2026, is expected to be repayable as follows (in thousands):
| Year | Amount | |||
| 2026 (remaining three months) | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| Total | $ | |||
Note 11. Equity
Stock-based compensation expense is recorded in salaries, wages and payroll taxes expense in the Condensed Consolidated Statements of Comprehensive Loss. For the nine months ended September 30, 2026 and 2025, stock-based compensation expense was approximately $
During the nine months ended September 30, 2026,
Preferred Stock
The Company has authorized
Common Stock
The Company has authorized
At-the-Market Offering Program
On May 13, 2026, the Company entered into a Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, pursuant to which the Company may offer and sell shares of its common stock, from time to time, having an aggregate offering price of up to approximately $
Sales of shares of the Company’s common stock under the ATM Program, if any, will be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market for the Company’s common stock. As of September 30, 2026,
Treasury Stock
Treasury stock represents shares of the Company’s common stock that have been issued and subsequently repurchased by the Company and that have not been retired or cancelled. The Company accounts for treasury stock under the cost method and includes treasury stock as a component of Total Equity on the Condensed Consolidated Balance Sheets. The Company accounts for the reissuance of treasury stock using the average cost method. The Company did not reissue or retire any shares of treasury stock during the nine months ended September 30, 2026.
Listing on the Nasdaq Capital Market
The Company’s common stock is traded on the Nasdaq Capital Market under the symbol “NXPL”.
Note 12. Related Party Transactions
The Company uses an American Express account for Orbital Satcom Corp and an American Express account for GTC, both in the name of the Company’s Chief Executive Officer and President, who personally guarantees the balance owed. As of September 30, 2026, the amount payable due to related party includes amounts due to the Company’s Chief Executive Officer and President. Total related party payments due as of September 30, 2026 and December 31, 2025 were approximately $
During the nine months ended September 30, 2026, the Company employed and paid wages to one employee related to the Company’s Chief Executive Officer and one employee related to the Company’s Chief Financial Officer.
Note 13. Commitments and Contingencies
Litigation
On October 28, 2024, Alan Jay Weisberg, the former Chief Executive Officer and Chairman of Progressive Care Inc. (“RXMD”), filed a putative class action suit on behalf of himself and all other former RXMD stockholders against NextPlat, Charles M. Fernandez, the former Chief Executive Officer and Executive Chairman of NextPlat, and Rodney Barreto, a director of NextPlat. The complaint purports to allege a breach of fiduciary duty by NextPlat and Messrs. Fernandez and Barreto in connection with the merger of RXMD with and into a wholly owned subsidiary of NextPlat (the “Merger”), which Merger was completed on October 1, 2024 following approval by the stockholders of each of NextPlat and RXMD in stockholder meetings held on September 13, 2024 by NextPlat and RXMD, respectively. Among other things, the complaint asserts that the consideration paid to Mr. Weisberg and the other RXMD stockholders in connection with the Merger was insufficient. The monetary relief requested in the complaint includes compensatory and rescissory damages in an unspecified dollar amount. The complaint is pending in the Court of Chancery of the State of Delaware. The caption is Alan Jay Weisberg v. Charles M. Fernandez, Rodney Barreto and NextPlat Corp., and the case number is C.A. No. 2024-1097-MTZ.
The Company believes the claims asserted in the action are without merit and intends to continue to vigorously defend against the lawsuit. The Company filed a motion to dismiss the complaint, which was denied by the court on December 3, 2025. Although the parties have engaged in discussions regarding a potential resolution of the matter, no agreement has been reached and there can be no assurance that the matter will be resolved on acceptable terms or at all. Oral argument on plaintiff's motion for class certification is scheduled for January 7, 2027. The parties have agreed to mediate the dispute. Based on currently available information and after consultation with legal counsel, management determined that a loss associated with this matter is probable and reasonably estimable in accordance with applicable accounting guidance. Accordingly, as of September 30, 2026, the Company has maintained an accrual of approximately $
From time to time, the Company may become involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. Other than the matter described above, the Company is not currently involved in any pending legal proceeding or litigation, and to the best of our knowledge, no governmental authority is contemplating any proceeding to which the Company is a party or to which any of the Company’s properties is subject, which would reasonably be likely to have a material adverse effect on the Company’s business, financial condition and operating results.
During the nine months ended September 30, 2026, the Company accrued an expense included in selling, general and administrative expenses of approximately $
Oscar Health Adjudication Suspension
On October 30, 2026, CVS Caremark (“Caremark”) notified PharmcoRx, a subsidiary of the Company, that, at the direction of Oscar Health (“Oscar”), PharmcoRx had been placed on an adjudication suspension for all claims adjudicated to Oscar plans, effective immediately. The suspension will remain in effect until Oscar’s investigation is resolved or until further notice. The notice states that Oscar’s request was based on an allegation it described as indicative of fraud, waste or abuse, but it does not identify any specific claim or conduct. Management believes the suspension relates to separate litigation Oscar brought concerning alleged fraud involving certain 340B entities. PharmcoRx is not a party to that litigation. The suspension applies only to PharmcoRx’s Hallandale Beach, Florida location. PharmcoRx has requested that Oscar lift the suspension or disclose its basis. Oscar did not respond by the requested date, and PharmcoRx is evaluating its options, including legal remedies.
Substantially all of PharmcoRx’s Oscar claims are dispensed as a contract pharmacy for 340B covered entities, for which PharmcoRx acts as an agent and recognizes a dispensing fee. PharmcoRx collects reimbursement from payers and remits it to the covered entities, net of its dispensing fee. At September 30, 2026, receivables from claims adjudicated to Oscar plans were approximately $
Oscar or Caremark could seek to recoup amounts previously paid on PharmcoRx’s Oscar claims. Under PharmcoRx’s contract pharmacy agreements, the covered entities are responsible for recoupments of claims for 340B drugs, less the dispensing fees PharmcoRx earned on those claims. PharmcoRx bears the risk that a covered entity does not pay amounts it owes. Oscar has not identified any claims or asserted any recoupment. The Company believes a loss is reasonably possible but not probable. Because Oscar has not identified the claims at issue, the Company cannot currently estimate the possible loss or range of loss. The Company has not recorded any adjustment related to this matter. Legal costs are expensed as incurred.
Note 14. Leases
Lease modification - Orlando, FL
During the nine months ended September 30, 2026, the Company modified a certain operating lease related to its Orlando pharmacy location. The modification primarily extended the lease term for
At the time of modification, the Company recorded an increase of approximately $
New pharmacy lease - Jacksonville, FL
On July 24, 2026, FPRX (the “Pharmacy”) entered into a lease agreement with 3604 University Blvd South Holdings LLC (the “landlord”) for approximately
The lease has an initial term of five years, commencing August 1, 2026 and expiring July 31, 2031. Base rent is payable monthly on a modified gross basis, beginning at approximately $
The lease modification and new lease have materially changed the Company’s future lease payment obligations, and the lease maturity schedule below has been updated as of September 30, 2026. The weighted average remaining lease term as of September 30, 2026 was
| Years Ending December 31, | Total Future Operating Lease Commitments | |||
| (in thousands) | ||||
| 2026 (remaining three months) | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| Total lease payments to be paid | ||||
| Less: future interest expense | ( | ) | ||
| Lease liabilities | ||||
| Less: current maturities | ( | ) | ||
| Long-term portion of lease liabilities | $ | |||
Subsequent events
Molino, FL lease. On October 1, 2026, the Company completed its acquisition of Scott’s Pharmacy (see Note 17. Subsequent Events). On the same date, Scott’s Pharmacy, a wholly owned subsidiary of the Company, signed a lease for approximately
| ● | options to extend for successive three-year terms |
| ● | a one-time option to lease adjoining space |
| ● | a right of first refusal |
| ● | an option to buy the entire property for $ |
The Company has concluded that it is not reasonably certain to exercise the renewal options or the purchase option. It will account for the arrangement as an operating lease and recognize a right-of-use asset and lease liability of approximately $
Nashville, TN lease. On October 28, 2026, Outfitter signed a new lease for approximately
Both leases commenced after September 30, 2026. Neither is included in the Company’s right-of-use assets, lease liabilities or maturity analysis of lease liabilities as of that date.
Note 15. Reportable Segments
The Company has two reportable segments: (i) e-Commerce Operations, which involves acquiring and leasing, primarily an e-commerce platform to collaborate with businesses to optimize their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue, and other related businesses and (ii) Healthcare Operations, which provides TPA, data management, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities and contracted fulfillment facilities, medication adherence packaging, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, and health practice risk management. This organizational structure aligns with how the Company’s CODMs manage the business, including resource allocation and performance assessment, and further aligns with the Company’s product categories and the key markets the Company serves.
The CODMs include the Company’s Chief Executive Officer and Chief Financial Officer.
The CODMs evaluate segment performance based on several factors, including Operating profit or loss, as a measure of operating segment performance which excludes the impact of Corporate overhead expenses. Corporate overhead expenses consist of executive compensation, stock-based compensation, public company expenses, litigation settlements, and depreciation. The CODMs do not review segment assets at a level different than what is reported in the Company’s Condensed Consolidated Balance Sheets. While the Company believes there are synergies between the two business segments, the segments are managed separately because each requires different business strategies. Accounting policies associated with the Company’s operating segments are generally the same as those described in Note 3 to our Annual Report on Form 10-K for the year ended December 31, 2025.
The following tables present a summary of the reportable segments (in thousands):
| For the Three Months Ended September 30, 2026 | e-Commerce Operations | Healthcare Operations | Eliminations | Total | ||||||||||||
| e-Commerce revenue | $ | $ | $ | $ | ||||||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||||||
| Pharmacy contract revenue | ||||||||||||||||
| Revenues, net | ||||||||||||||||
| Segment expenses: | ||||||||||||||||
| Cost of revenue | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Salaries, wages and payroll taxes | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Intangible asset amortization | ||||||||||||||||
| Total segment expenses | ||||||||||||||||
| Segment operating (loss) income | $ | ( | ) | $ | ||||||||||||
| Corporate overhead expenses | ||||||||||||||||
| Non-operating income | ( | ) | ||||||||||||||
| Loss before income taxes | ( | ) | ||||||||||||||
| Income taxes | ||||||||||||||||
| Net loss | $ | ( | ) | |||||||||||||
| For the Three Months Ended September 30, 2025 | e-Commerce Operations | Healthcare Operations | Eliminations | Total | ||||||||||||
| e-Commerce revenue | $ | $ | $ | $ | ||||||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||||||
| Pharmacy contract revenue | ||||||||||||||||
| Revenues, net | ||||||||||||||||
| Segment expenses: | ||||||||||||||||
| Cost of revenue | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Salaries, wages and payroll taxes | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Intangible asset amortization | ||||||||||||||||
| Total segment expenses | ||||||||||||||||
| Segment operating loss | $ | ( | ) | $ | ( | ) | — | ( | ) | |||||||
| Corporate overhead expenses | ||||||||||||||||
| Non-operating income | ( | ) | ||||||||||||||
| Loss before income taxes | ( | ) | ||||||||||||||
| Income taxes | ||||||||||||||||
| Net loss | $ | ( | ) | |||||||||||||
| For the Nine Months Ended September 30, 2026 | e-Commerce Operations | Healthcare Operations | Eliminations | Total | ||||||||||||
| e-Commerce revenue | $ | $ | $ | $ | ||||||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||||||
| Pharmacy contract revenue | ||||||||||||||||
| Revenues, net | ||||||||||||||||
| Segment expenses: | ||||||||||||||||
| Cost of revenue | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Salaries, wages and payroll taxes | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Intangible asset amortization | ||||||||||||||||
| Total segment expenses | ||||||||||||||||
| Segment operating income | $ | $ | ||||||||||||||
| Corporate overhead expenses | ||||||||||||||||
| Non-operating income | ( | ) | ||||||||||||||
| Loss before income taxes | ( | ) | ||||||||||||||
| Income taxes | ( | ) | ||||||||||||||
| Net loss | $ | ( | ) | |||||||||||||
| For the Nine Months Ended September 30, 2025 | e-Commerce Operations | Healthcare Operations | Eliminations | Total | ||||||||||||
| e-Commerce revenue | $ | $ | $ | $ | ||||||||||||
| Pharmacy prescription and other revenue, net of PBM fees | ||||||||||||||||
| Pharmacy contract revenue | ||||||||||||||||
| Revenues, net | ||||||||||||||||
| Segment expenses: | ||||||||||||||||
| Cost of revenue | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Salaries, wages and payroll taxes | ||||||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Intangible asset amortization | ||||||||||||||||
| Total segment expenses | ||||||||||||||||
| Segment operating loss | $ | ( | ) | $ | ( | ) | — | ( | ) | |||||||
| Corporate overhead expenses | ||||||||||||||||
| Non-operating income | ( | ) | ||||||||||||||
| Loss before income taxes | ( | ) | ||||||||||||||
| Income taxes | ( | ) | ||||||||||||||
| Net loss | $ | ( | ) | |||||||||||||
| e-Commerce Operations | Healthcare Operations | Eliminations | Total | |||||||||||||
| Total assets as of September 30, 2026 | $ | $ | $ | $ | ||||||||||||
| Total assets as of December 31, 2025 | $ | $ | $ | $ | ||||||||||||
Note 16. Concentrations
e-Commerce operations concentrations:
Customers:
Amazon accounted for approximately
Suppliers:
The following table sets forth information as to each supplier that accounted for 10% or more of the purchases related to e-Commerce Operations for the three and nine months ended September 30, 2026 and 2025 (in thousands):
| For the Three Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | |||||||||||||||
| Amount | % of Total Purchases | Amount | % of Total Purchases | |||||||||||||
| Iridium Satellite | $ | % | $ | % | ||||||||||||
| Garmin | $ | % | $ | % | ||||||||||||
| For the Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | |||||||||||||||
| Amount | % of Total Purchases | Amount | % of Total Purchases | |||||||||||||
| Iridium Satellite | $ | % | % | |||||||||||||
| Garmin | $ | % | % | |||||||||||||
| Globalstar | $ | % | % | |||||||||||||
Geographic:
The following table sets forth revenue as to each geographic location (in thousands):
| For the Three Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | |||||||||||||||
| Amount | % of Total | Amount | % of Total | |||||||||||||
| Europe | $ | % | $ | % | ||||||||||||
| North America | % | % | ||||||||||||||
| Asia & Pacific | % | % | ||||||||||||||
| South America | 1 | % | — | |||||||||||||
| Africa | % | |||||||||||||||
| $ | % | $ | % | |||||||||||||
| For the Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | |||||||||||||||
| Amount | % of Total | Amount | % of Total | |||||||||||||
| Europe | $ | % | $ | % | ||||||||||||
| North America | % | % | ||||||||||||||
| Asia & Pacific | % | % | ||||||||||||||
| Africa | % | % | ||||||||||||||
| South America | 1 | % | — | |||||||||||||
| $ | % | $ | % | |||||||||||||
Healthcare operations concentrations:
Suppliers:
Progressive Care had significant concentrations with one vendor, McKesson. The purchases from this significant vendor were approximately
Customers:
Progressive Care’s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not reimburse Progressive Care.
Reimbursements from the top three significant PBMs were as follows:
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| A | % | % | ||||||
| B | % | % | ||||||
| C | % | % | ||||||
Note 17. Subsequent Events
The Company has evaluated subsequent events through the date of this filing, the date the condensed consolidated financial statements were available to be issued.
Pharmacy Acquisition
On July 14, 2026, Progressive entered into a Membership Interest Purchase Agreement (the “Agreement”) with Ron G. Scott (the “Seller”) to acquire
The purchase price was $
The Seller’s indemnification obligations are generally capped at 10% of the purchase price, except in the case of fraud, and the Company provided reciprocal indemnification. At closing, the Seller entered into a three-year noncompetition agreement covering Escambia County, Florida, and the Company entered into a lease agreement for Scott’s Pharmacy’s premises - see Note 14. Leases for further information of the lease.
The acquisition will be accounted for as a business combination under ASC 805, Business Combinations. Because the acquisition closed shortly before these financial statements were issued, the initial accounting for the business combination was incomplete. This includes the valuation of the assets acquired and liabilities assumed, such as inventory, prescription files, the noncompetition agreement, and any goodwill. As a result, the Company is not yet able to provide the purchase price allocation, the amount of goodwill (including the amount expected to be deductible for tax purposes), or the pro forma revenue and earnings information required by ASC 805. The results of Scott’s Pharmacy will be included in the Company’s consolidated financial statements beginning October 1, 2026.
New Operating Lease - Nashville, TN
On October 28, 2026, Outfitter signed a new lease for approximately
At-the-Market Offering Agreement
On May 13, 2026, the Company entered into a Sales Agreement with H.C. Wainwright & Co., LLC establishing an at-the-market equity offering program (the “ATM Program”) with an aggregate offering price of approximately $
Oscar Health Adjudication Suspension
On October 30, 2026, Caremark notified PharmcoRx that, at Oscar’s direction, PharmcoRx had been placed on an adjudication suspension for all claims adjudicated to Oscar plans, effective immediately, until Oscar's investigation is resolved or until further notice. The notice states that Oscar’s request was based on an allegation it described as indicative of fraud, waste or abuse, but it does not identify any specific claim or conduct. The suspension applies only to claims adjudicated to Oscar plans at PharmcoRx’s Hallandale Beach, Florida location, and does not affect PharmcoRx’s other pharmacy locations. Caremark stated that it does not otherwise affect PharmcoRx’s participation in the Caremark network.
PharmcoRx has requested that Oscar lift the suspension or disclose its basis. Oscar did not respond by the requested date, and PharmcoRx is evaluating its options, including legal remedies. For the nine months ended September 30, 2026, pharmacy contract revenue from claims adjudicated to Oscar plans was approximately $
The following information should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained elsewhere in this report. Statements made in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Quarterly Report on Form 10-Q that do not consist of historical facts, are “forward-looking statements.” Statements accompanied or qualified by, or containing words such as “may,” “will,” “should,” “believes,” “expects,” “intends,” “plans,” “projects,” “estimates,” “predicts,” “potential,” “outlook,” “forecast,” “anticipates,” “presume,” and “assume” constitute forward-looking statements, and as such, are not a guarantee of future performance. The statements involve factors, risks and uncertainties, the impact or occurrence of which can cause actual results to differ materially from the expected results described in such statements. Risks and uncertainties can include, among others, fluctuations in general business cycles and changing economic conditions; changing product demand and industry capacity; increased competition and pricing pressures; advances in technology that can reduce the demand for the Company’s products, as well as other factors, many or all of which may be beyond the Company’s control. Consequently, investors should not place undue reliance upon forward-looking statements as predictive of future results. The Company disclaims any obligation to update the forward-looking statements in this report.
We encourage you to review our periodic reports filed with the SEC and included in the SEC’s EDGAR database, including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026, and our subsequent public filings with the SEC.
Overview
NextPlat Corp operates through two primary business segments: e-Commerce Operations and Healthcare Operations. Our strategy is focused on expanding global e-Commerce distribution of satellite communication products and services while continuing to grow our healthcare platform through pharmacy services and healthcare data analytics solutions.
Our e-Commerce Operations segment distributes satellite communications equipment, connectivity solutions, and related services through proprietary websites and third-party marketplaces. These products enable voice, data, tracking, and emergency communications in remote environments where traditional terrestrial communications infrastructure may be unavailable or unreliable. We generate revenue primarily from the sale of satellite communication devices and related equipment, as well as recurring revenue from satellite airtime and connectivity service plans.
Our Healthcare Operations segment operates through Progressive Care LLC and its pharmacy and healthcare technology subsidiaries. This segment provides prescription pharmaceuticals, medication therapy management services, long-term care pharmacy support, and healthcare analytics solutions. The segment also participates in the federal 340B Drug Pricing Program through contract pharmacy arrangements, which contributes meaningfully to pharmacy segment margins.
Recent Developments
Oscar Health adjudication suspension
On October 30, 2026, Caremark notified PharmcoRx that, at Oscar’s direction, PharmcoRx had been placed on an adjudication suspension for all claims adjudicated to Oscar plans, effective immediately, until Oscar’s investigation is resolved or until further notice. The notice states that Oscar’s request was based on an allegation it described as indicative of fraud, waste or abuse, but it does not identify any specific claim or conduct. The suspension applies only to claims adjudicated to Oscar plans at PharmcoRx’s Hallandale Beach, Florida location, and does not affect PharmcoRx’s other pharmacy locations. Caremark stated that it does not otherwise affect PharmcoRx’s participation in the Caremark network. PharmcoRx has requested that Oscar lift the suspension or disclose its basis. Oscar did not respond by the requested date, and PharmcoRx is evaluating its options, including legal remedies.
Substantially all of PharmcoRx’s Oscar claims are dispensed as a contract pharmacy for 340B covered entities. For these claims, PharmcoRx acts as an agent and recognizes only a dispensing fee, so the reimbursement it collects and remits to covered entities is not included in our revenue. For the nine months ended September 30, 2026, pharmacy contract revenue from claims adjudicated to Oscar plans was approximately $2.3 million, or 7% of consolidated revenue, on gross Oscar reimbursement of approximately $19.0 million. While the suspension continues, we will not earn revenue on prescriptions for Oscar members. We expect this to reduce revenue by approximately $0.3 million per month while under the suspension. Some patients may also move their prescriptions to other pharmacies and not return after the suspension ends.
At September 30, 2026, receivables from Oscar claims were approximately $2.5 million, and related net amounts payable to covered entities were $2.0 million. PharmcoRx is generally not required to remit reimbursement to covered entities until it is received. Under its contract pharmacy agreements, covered entities are responsible for recoupments, less PharmcoRx’s dispensing fees. If Oscar or Caremark were to seek recoupment, PharmcoRx could be required to fund amounts before it recovers them from covered entities, which could affect our liquidity. See Note 13. Commitments and Contingencies to the condensed consolidated financial statements and Part II, Item 1A, “Risk Factors.”
Critical Accounting Policies and Estimates
The significant accounting policies of the Company were described in Note 3 to the Audited Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2025. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2025 Form 10-K. The most recently adopted accounting pronouncements and accounting pronouncements to be adopted by the Company are described in Note 3 in the Notes to our Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.
Results of Operations for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 (in thousands):
| Three Months Ended September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Revenues, net |
$ | 10,499 | $ | 13,752 | $ | (3,253 | ) | (24 | )% | |||||||
| Cost of revenue |
6,821 | 11,022 | (4,201 | ) | (38 | )% | ||||||||||
| Gross profit |
3,678 | 2,730 | 948 | 35 | % | |||||||||||
| Operating expenses |
4,455 | 4,969 | (514 | ) | (10 | )% | ||||||||||
| Operating loss |
(777 | ) | (2,239 | ) | 1,462 | 65 | % | |||||||||
| Non-operating (income) expense |
(9 | ) | (28 | ) | 19 | 68 | % | |||||||||
| Loss before income taxes |
(768 | ) | (2,211 | ) | 1,443 | 65 | % | |||||||||
| Income taxes |
20 | 26 | (6 | ) | (23 | )% | ||||||||||
| Net loss attributable to common stockholders |
$ | (748 | ) | $ | (2,185 | ) | $ | 1,437 | 66 | % | ||||||
We recognized overall revenue from operations of approximately $10.5 million and $13.8 million, an overall decrease of approximately $3.3 million, for the three months ended September 30, 2026, when compared to the three months ended September 30, 2025. The decrease in revenue was primarily attributable to the decrease of approximately $3.4 million from Healthcare Operations.
Gross margin increased from approximately 20% for the three months ended September 30, 2025, to approximately 35% for the three months ended September 30, 2026. The increase in gross margin during the third quarter of 2026 compared to the same period in 2025 was attributable to the increase in volume of pharmacy contract revenue in the Healthcare Operations segment. Gross margin for Healthcare Operations increased for the third quarter of 2026 to approximately 41% from 18% when compared to the same period in 2025 and was attributable to new contracted medication fulfillment services, the increase in volume of 340B contract pharmacy services, and the improved drug costing as a result of the Medicare Maximum Fair Price program which began in January 2026. Gross profit margin for e-Commerce Operations remained consistent for the third quarter of 2026 at approximately 24% when compared to the same period in 2025.
Operating loss decreased by approximately $1.5 million for the three months ended September 30, 2026, when compared to the three months ended September 30, 2025, as a result of the increase in gross profit of approximately $0.9 million and the decrease in operating expenses of approximately $0.5 million. See detailed discussion below.
Revenue
Our revenues were as follows (in thousands):
| Three Months Ended September 30, |
||||||||||||||||||||||||
| 2026 |
2025 |
|||||||||||||||||||||||
| Dollars |
% of Revenue |
Dollars |
% of Revenue |
$ Change |
% Change |
|||||||||||||||||||
| e-Commerce revenue |
$ | 3,820 | 36 | % | $ | 3,702 | 27 | % | $ | 118 | 3 | % | ||||||||||||
| Pharmacy prescription revenue, net |
4,317 | 41 | % | 9,459 | 69 | % | (5,142 | ) | (54 | )% | ||||||||||||||
| Pharmacy contract revenue |
2,362 | 23 | % | 591 | 4 | % | 1,771 | 300 | % | |||||||||||||||
| Revenues, net |
$ | 10,499 | 100 | % | $ | 13,752 | 100 | % | $ | (3,253 | ) | (24 | )% | |||||||||||
Our net revenues consist of e-Commerce sales of satellite phones, tracking devices, accessories and airtime plans; pharmacy prescription revenues; and pharmacy contract revenues. For the three months ended September 30, 2026, overall revenues were approximately $10.5 million compared to $13.8 million for the three months ended September 30, 2025, a decrease of approximately $3.3 million or 23.7%.
e-Commerce revenue slightly increased to approximately $3.8 million for the three months ended September 30, 2026 compared to $3.7 million for the three months ended September 30, 2025.
Pharmacy prescription revenue, net was approximately $4.3 million and $9.5 million for the three months ended September 30, 2026 and 2025, respectively, a decrease of approximately $5.1 million. The decrease was primarily driven by lower reimbursement rates of approximately $3.6 million and a reduction in prescription volume of approximately $1.5 million, reflecting the changes in payer reimbursement rates and overall payer mix. Gross margin was approximately 11% for the third quarter of 2026, compared to approximately 13% in the prior year period.
Pharmacy contract revenue was approximately $2.4 million and $0.6 million for the three months ended September 30, 2026 and 2025, respectively, an increase of approximately $1.8 million. The increase was attributable to the increase in 340B contract revenue of approximately $1.6 million and the increase in medication fulfillment contract services (secured late in 2025) of approximately $0.2 million. The increase in 340B contract revenue was driven by an increase in our existing 340B contracts of approximately $1.0 million and an increase in new 340B contract revenue of approximately $0.6 million.
Operating Expenses
Our operating expenses were as follows (in thousands):
| Three Months Ended September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Selling, general and administrative |
$ | 2,032 | $ | 1,899 | $ | 133 | 7 | % |
||||||||
| Salaries, wages and payroll taxes |
2,347 | 2,665 | (318 | ) | (12 | )% |
||||||||||
| Depreciation and amortization |
51 | 130 | (79 | ) | (61 | )% |
||||||||||
| Intangible asset amortization |
25 | 25 | — | — | % | |||||||||||
| Loss on settlement of litigation |
— | 250 | (250 | ) | (100 | )% | ||||||||||
| Operating expenses |
$ | 4,455 | $ | 4,969 | $ | (514 | ) | (10 | )% |
|||||||
Significant changes in operating expenses were as follows:
• Selling, general and administrative increased approximately $0.1 million for the three months ended September 30, 2026, when compared to the prior year period, primarily as a result of an increase in professional fees of approximately $0.1 million, which consist of accounting fees, legal fees, and public company expenses.
• Salaries, wages and payroll taxes were approximately $2.4 million and $2.7 million for the three months ended September 30, 2026 and 2025, respectively, a decrease of approximately $0.3 million or 11.9%. The decrease was attributable to a decrease in stock-based compensation of approximately $0.1 million and a decrease in total headcount expenses of approximately $0.2 million. The reduction in headcount was primarily driven by operational efficiencies and strategic workforce realignment within our healthcare operations.
• Depreciation and amortization decreased approximately $0.1 million for the three months ended September 30, 2026, when compared to the prior year period, primarily as a result of certain assets reaching the end of their useful lives.
• There was no loss on settlement of litigation for the three months ended September 30, 2026 compared to approximately $0.3 million in the prior year period.
Non-operating Income
Non-operating income was approximately $9.0 thousand for the three months ended September 30, 2026, compared to approximately $28.0 thousand for the three months ended September 30, 2025. The change was primarily due to a decrease in interest earned of approximately $51.0 thousand due to the decrease in cash on hand, a loss on sale or disposal of property and equipment recognized in the prior year of approximately $36.0 thousand, and a change in foreign currency rates of approximately $6.0 thousand.
Net Loss
We recorded net losses of approximately $0.8 million and $2.2 million for the three months ended September 30, 2026 and 2025, respectively. The change in net loss was a result of the factors described above.
Results of Operations for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 (in thousands):
| Nine Months Ended September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Revenues, net |
$ | 32,235 | $ | 40,918 | $ | (8,683 | ) | (21 | )% | |||||||
| Cost of revenue |
20,451 | 32,441 | (11,990 | ) | (37 | )% | ||||||||||
| Gross profit |
11,784 | 8,477 | 3,307 | 39 | % | |||||||||||
| Operating expenses |
13,791 | 14,629 | (838 | ) | (6 | )% | ||||||||||
| Operating loss |
(2,007 | ) | (6,152 | ) | 4,145 | 67 | % | |||||||||
| Non-operating (income) expense |
(11 | ) | (250 | ) | 239 | 96 | % | |||||||||
| Loss before income taxes |
(1,996 | ) | (5,902 | ) | 3,906 | 66 | % | |||||||||
| Income taxes |
(28 | ) | (14 | ) | (14 | ) | (100 | )% | ||||||||
| Net loss |
(2,024 | ) | (5,916 | ) | 3,892 | 66 | % | |||||||||
| Net loss attributable to non-controlling interest |
14 | — | 14 | — | % | |||||||||||
| Net loss attributable to common stockholders |
$ | (2,010 | ) | $ | (5,916 | ) | $ | 3,906 | 66 | % | ||||||
We recognized overall revenue from operations of approximately $32.2 million and $40.9 million, an overall decrease of approximately $8.7 million, for the nine months ended September 30, 2026, when compared to the nine months ended September 30, 2025. The decrease in revenue was attributable to the decrease of approximately $9.0 million from Healthcare Operations, which was partially offset by an increase of approximately $0.3 million from e-Commerce Operations.
Gross margin increased from approximately 21% for the nine months ended September 30, 2025, to approximately 37% for the nine months ended September 30, 2026. The increase in gross margin during the nine months ended September 30, 2026 compared to the same period in 2025 was attributable to the increase in volume of pharmacy contract revenue in the Healthcare Operations segment. Gross margin for Healthcare Operations increased for the nine months ended September 30, 2026 to approximately 42% from 19% when compared to the same period in 2025 and was attributable to new contracted medication fulfillment services, the increase in volume of 340B contract pharmacy services, as well as the improved drug costing as a result of the Medicare Maximum Fair Price program which began in January 2026. Gross profit margin for e-Commerce Operations remained consistent for the nine months ended September 30, 2026 at approximately 25% when compared to the same period in 2025.
Operating loss decreased by approximately $4.1 million for the nine months ended September 30, 2026, when compared to the nine months ended September 30, 2025, as a result of the decrease in operating expenses of approximately $0.8 million, and the increase in gross profit of approximately $3.3 million. See detailed discussion below.
Revenue
Our revenues were as follows (in thousands):
| Nine Months Ended September 30, |
||||||||||||||||||||||||
| 2026 |
2025 |
|||||||||||||||||||||||
| Dollars |
% of Revenue |
Dollars |
% of Revenue |
$ Change |
% Change |
|||||||||||||||||||
| e-Commerce revenue |
$ | 11,097 | 34 | % | $ | 10,828 | 27 | % | $ | 269 | 2 | % | ||||||||||||
| Pharmacy prescription and other revenue, net of PBM fees |
14,665 | 46 | % | 27,123 | 66 | % | (12,458 | ) | (46 | )% | ||||||||||||||
| Pharmacy contract revenue |
6,473 | 20 | % | 2,967 | 7 | % | 3,506 | 118 | % | |||||||||||||||
| Revenues, net |
$ | 32,235 | 100 | % | $ | 40,918 | 100 | % | $ | (8,683 | ) | (21 | )% | |||||||||||
Our net revenues consist of e-Commerce sales of satellite phones, tracking devices, accessories and airtime plans; pharmacy prescription revenues; and pharmacy contract revenues. For the nine months ended September 30, 2026, overall revenues were approximately $32.2 million compared to $40.9 million for the nine months ended September 30, 2025, a decrease of approximately $8.7 million or 21.2%.
e-Commerce revenue was approximately $11.1 million and $10.8 million for the nine months ended September 30, 2026 and 2025, respectively, an increase of approximately $0.3 million primarily due to the increase in airtime sales.
Pharmacy prescription revenue, net was approximately $14.7 million and $27.1 million for the nine months ended September 30, 2026 and 2025, respectively, a decrease of approximately $12.5 million. The decrease was primarily driven by lower reimbursement rates of approximately $8.1 million and a reduction in prescription volume of approximately $4.3 million, reflecting the changes in payer reimbursement rates and overall payer mix. Despite the decline in revenue and prescription count, gross margin significantly improved to approximately 18% from approximately 11% in the prior year period. This improvement was driven by higher gross profit per prescription reflecting a shift in dispensing mix and continued margin discipline. Additionally, beginning in the first quarter of 2026, the implementation of the Medicare Maximum Fair Price program impacted reimbursement on certain Medicare prescriptions. As a result, certain prescriptions that were previously dispensed at lower margins in the prior year period generated improved margins under the updated reimbursement framework, contributing to the increase in overall gross profit.
Pharmacy contract revenue was approximately $6.5 million and $3.0 million for the nine months ended September 30, 2026 and 2025, respectively, an increase of approximately $3.5 million. The increase was attributable to the increase in 340B contract revenue of approximately $2.0 million and the increase in medication fulfillment contract services (secured late in 2025) of approximately $1.5 million. The increase in 340B contract revenue was driven by an increase in our existing 340B contracts of approximately $1.5 million and an increase in new 340B contract revenue of approximately $0.5 million.
Operating Expenses
Our operating expenses were as follows (in thousands):
| Nine Months Ended September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Selling, general and administrative |
$ | 6,483 | $ | 5,924 | $ | 559 | 9 | % | ||||||||
| Salaries, wages and payroll taxes |
7,062 | 7,929 | (867 | ) | (11 | )% | ||||||||||
| Depreciation and amortization |
170 | 450 | (280 | ) | (62 | )% | ||||||||||
| Intangible asset amortization |
76 | 76 | — | — | % | |||||||||||
| Loss on settlement of litigation |
— | 250 | (250 | ) | (100 | )% | ||||||||||
| Operating expenses |
$ | 13,791 | $ | 14,629 | $ | (838 | ) | (6 | )% | |||||||
Significant changes in operating expenses were as follows:
• Selling, general and administrative increased approximately $0.6 million for the nine months ended September 30, 2026, when compared to the prior year, primarily as a result of an increase in professional fees of approximately $0.8 million, which consist of accounting fees, legal fees, and public company expenses (including $0.4 million of expense related to liquidated damages obligations pursuant to the Registration Rights Agreement dated December 8, 2022), partially offset by a decrease in insurance expense of approximately $0.2 million.
• Salaries, wages and payroll taxes were approximately $7.1 million and $7.9 million for the nine months ended September 30, 2026 and 2025, respectively, a decrease of approximately $0.9 million or 10.9%. The decrease was attributable to a decrease in executive compensation of approximately $0.3 million and a decrease in total headcount expenses of approximately $0.9 million, partially offset by an increase in stock-based compensation of approximately $0.2 million. The reduction in headcount was primarily driven by operational efficiencies and strategic workforce realignment within our healthcare operations.
• Depreciation and amortization decreased approximately $0.3 million for the nine months ended September 30, 2026, when compared to the prior year, primarily as a result of certain assets reaching the end of their useful lives.
• There was no loss on settlement of litigation for the nine months ended September 30, 2026 compared to approximately $0.3 million in the prior year.
Non-operating Income
Non-operating income was approximately $11.0 thousand for the nine months ended September 30, 2026, compared to approximately $0.3 million for the nine months ended September 30, 2025. The change was primarily due to a decrease in interest earned of approximately $0.2 million due to the decrease in cash on hand, a loss on sale or disposal of property and equipment recognized in the prior year of approximately $0.2 million, and a loss on the change in foreign currency rates of approximately $0.3 million.
Net Loss
We recorded net losses of approximately $2.0 million and $5.9 million for the nine months ended September 30, 2026 and 2025, respectively. The change in net loss was a result of the factors described above.
Liquidity and Capital Resources
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. As of September 30, 2026, we had a cash balance of approximately $11.2 million. Our working capital was approximately $13.5 million at September 30, 2026. Our principal uses of cash include (i) purchases of pharmaceutical inventory and e-Commerce product inventory, (ii) operating expenses, including payroll, professional services, and public company expenses, (iii) technology development and platform investments, and (iv) potential acquisitions and strategic investments. We continue to closely monitor our cash position and operating expenditures. In response to recent trends and in alignment with our long-term strategic goals, we continue to implement a series of cost reduction measures aimed at improving operational efficiency and preserving liquidity. These measures include optimizing our delivery process and renegotiating certain vendor agreements. While we remain committed to investing in key growth initiatives, we are prioritizing financial discipline to ensure we maintain adequate liquidity to support ongoing operations and strategic objectives. In addition, management is exploring various options with respect to strategic alternatives to diversify our business operations, including opportunities in additional services, joint ventures, and other collaborative structures.
As described under “Recent Developments,” on October 30, 2026, PharmcoRx was placed on an adjudication suspension for all claims adjudicated to Oscar plans at its Hallandale Beach, Florida location. While the suspension continues, we will not earn dispensing fees on prescriptions for Oscar members, which we expect to reduce revenue by approximately $0.3 million per month beginning in the fourth quarter of 2026.
At-the-Market Offering Program
On May 13, 2026, we entered into a Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, pursuant to which we may offer and sell shares of our common stock, from time to time, having an aggregate offering price of up to approximately $3.8 million, through or to the sales agent(s) acting as our agent or principal (the “ATM Program”).
Sales of shares of our common stock under the ATM Program, if any, will be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market for our common stock.
We intend to use the net proceeds from any sales under the ATM Program for general corporate purposes, which may include working capital, capital expenditures, repayment of indebtedness, and potential acquisitions or strategic investments. We are not obligated to make any sales under the ATM Program and may suspend or terminate the offering at any time.
We will pay the sales agent(s) a commission of up to 3.0% of the gross proceeds from any shares sold under the Sales Agreement.
As of the date of filing this Quarterly Report on Form 10-Q, the Company has sold 16,610 shares under the ATM Program at an average price of $8.74 for total gross proceeds of approximately $0.1 million.
Going Concern and Management’s Plans
As described in Note 4 to the Condensed Consolidated Financial Statements, the Company has incurred recurring operating losses and historically generated negative operating cash flows, and these conditions raised substantial doubt about the Company’s ability to continue as a going concern for the twelve months following the issuance of these financial statements. Management has evaluated its plans to mitigate these conditions, which include expanding the Company's long-term care pharmacy operations, increasing 340B contract pharmacy revenue, developing additional institutional medication fulfillment contracts, implementing identified operational efficiencies, and utilizing the ATM Program. Management also considered the adjudication suspension imposed on October 30, 2026 on PharmcoRx's Hallandale Beach, Florida location for claims adjudicated to Oscar Health plans. For the nine months ended September 30, 2026, revenue from these claims was approximately $2.3 million, or 7% of consolidated revenue (see Item 1 of Part I, “Notes to Condensed Consolidated Financial Statements – Note 13. Commitments and Contingencies, and Note 17. Subsequent Events”). For the nine months ended September 30, 2026, as compared to the prior year, operating loss decreased to approximately $2.0 million from $6.2 million, and cash used in operating activities decreased to approximately $2.1 million from $5.8 million. As of September 30, 2026, the Company had cash of approximately $11.2 million and $3.8 million of remaining availability under the ATM Program. As of the date of filing this Quarterly Report on Form 10-Q, the Company has sold 16,610 shares under the ATM Program at an average price of $8.74 for total gross proceeds of approximately $0.1 million. Based on these results, management's projections of operating results and cash flows for the twelve months following issuance, and the Company's liquidity position, management has concluded that its plans, which are probable of being effectively implemented and probable of mitigating the relevant conditions, alleviate the substantial doubt about the Company’s ability to continue as a going concern.
As of the date of filing this Quarterly Report on Form 10-Q, the Company’s existing cash resources are sufficient to support planned operations for the next 12 months. As a result, management believes that the existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of the consolidated financial statements.
Our long-term cash requirements (beyond the next 12 months from filing this Quarterly Report on Form 10-Q) include lease obligations, note payable obligations, and potential capital investments in technology development and strategic acquisitions. We anticipate funding these long-term requirements through cash generated from operations, available cash on hand, and, if necessary, proceeds from future equity or debt financings. We do not have any material commitments for capital expenditures as of September 30, 2026.
Pharmacy Acquisition
On July 14, 2026, we entered into a Membership Interest Purchase Agreement (the “Agreement”) with Ron G. Scott (the “Seller”) to acquire 100% of the membership interests in Scott’s Pharmacy, LLC, a community pharmacy in Molino, Florida (“Scott’s Pharmacy”). On October 1, 2026, we completed the transaction for approximately $1.5 million in cash. For additional information, see Item 1 of Part I, “Notes to Condensed Consolidated Financial Statements – Note 17. Subsequent Events.”
The following table summarizes our cash flows (in thousands):
| For the Nine Months Ended September 30, |
||||||||
| 2026 |
2025 |
|||||||
| Net change in cash from: |
||||||||
| Operating activities |
$ | (2,065 | ) | $ | (5,828 | ) | ||
| Investing activities |
(76 | ) | 200 | |||||
| Financing activities |
(360 | ) | (358 | ) | ||||
| Effect of exchange rate on cash |
12 | (48 | ) | |||||
| Change in cash |
(2,489 | ) | (6,034 | ) | ||||
| Cash at end of period |
$ | 11,220 | $ | 13,926 | ||||
Cash Flow from Operating Activities
Net cash used in operating activities totaled approximately $2.1 million and $5.8 million for the nine months ended September 30, 2026 and 2025, respectively, and changed by approximately $3.8 million period-over-period. The favorable change of approximately $3.8 million was primarily attributable to the following:
• a decrease in cash received from e-Commerce Operations of approximately $1.8 million due to the year-over-year timing of collections of outstanding receivables;
• a decrease in cash received from Healthcare Operations of approximately $6.9 million due to the year-over-year revenue decrease and the timing of collections of outstanding receivables;
• a decrease in cash paid for inventory purchases and other costs of revenue of approximately $13.1 million;
• a decrease in cash paid for salaries and related expenses of approximately $1.3 million due to the decrease in executive compensation and decreased headcount; and
• an increase in cash paid for other recurring operating expenses of approximately $1.2 million due to the timing of payables.
Cash Flow from Investing Activities
Net cash used in investing activities for the nine months ended September 30, 2026 was approximately $0.1 million for the purchase of property and equipment. Net cash provided by investing activities for the nine months ended September 30, 2025 was approximately $0.2 million, primarily attributable to the sales of vehicles for our Healthcare Operations delivery fleet.
Cash Flow from Financing Activities
Net cash used in financing activities was approximately $0.4 million for the nine months ended September 30, 2026 and was attributable to the repayment of notes payable. Net cash used in financing activities was approximately $0.4 million for the nine months ended September 30, 2025 and was attributable to the repayment of notes payable and repurchases of common shares.
Off-Balance Sheet Arrangements
We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our condensed consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company, as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, we are not required to provide the information required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
(a) Evaluation of disclosure controls and procedures. In accordance with Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (“Exchange Act”) we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness and design of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our CEO and CFO have concluded that as of September 30, 2026, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
Identification of Material Weakness
As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, management identified material weaknesses related to (i) the accounting estimate of a PBM performance bonus receivable and (ii) the accounting for the valuation of the modification of certain PIPE warrants. The material weaknesses related to the PBM performance bonus receivable and PIPE warrant modification remained unremediated as of September 30, 2026.
Remediation Plans
Management is committed to improving its internal control over financial reporting and remediating the material weaknesses described above as quickly as possible. Management has outlined a remediation plan to ensure that the control deficiencies are remediated. Management will continue to evaluate the design and operating effectiveness of the controls. The material weaknesses will not be considered remediated until the controls have operated effectively for a sufficient period of time and management has completed testing to conclude that the controls are effective.
Accounting Estimate of PBM Performance Bonus Receivable
To address the material weakness related to the estimation of performance-based bonus receivables, management implemented the following actions as of September 30, 2026: (i) established a standardized quarterly process for estimating performance-based bonus receivables, including documented estimates retrieved timely from third-party adherence data and performance metrics and (ii) designed and implemented documented review controls performed by senior management to evaluate the reasonableness of the estimate. These controls operated during each of the first, second and third quarters of 2026. Management has substantially completed testing of the design and operating effectiveness of these controls. Management expects to conclude on the remediation of this material weakness as of December 31, 2026, subject to the controls continuing to operate effectively for a sufficient period of time and the completion of management’s testing.
PIPE Warrant Modification
To address the material weakness related to the accounting for the valuation of the modification of certain PIPE warrants, specifically the extension of expiration dates, management has initiated the following actions: (i) establishing controls to ensure timely identification of modifications to outstanding warrants, including enhanced coordination and communication protocols between finance, legal, and executive management when contractual terms are amended; (ii) implementing valuation controls requiring the preparation of detailed valuation analyses for modified warrants; (iii) engaging qualified third-party valuation specialists to assist in the valuation of warrant modifications and to support management’s accounting conclusions for complex or non-routine transactions; and (iv) designing and implementing documented review controls performed by individuals with appropriate technical expertise to evaluate classification conclusions, valuation methodologies and assumptions, and the completeness and accuracy of financial statement impacts.
(b) Inherent Limitations on Controls. Management, including the CEO and CFO, does not expect that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
(c) Changes in internal controls over financial reporting. Other than ongoing remediation activities related to the material weaknesses described above, there were no changes in our internal control over financial reporting during our fiscal quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On October 28, 2024, Alan Jay Weisberg, the former Chief Executive Officer and Chairman of Progressive Care Inc. (“RXMD”), filed a putative class action suit on behalf of himself and all other former RXMD stockholders against NextPlat, Charles M. Fernandez, the former Chief Executive Officer and Executive Chairman of NextPlat, and Rodney Barreto, a director of NextPlat. The complaint purports to allege a breach of fiduciary duty by NextPlat and Messrs. Fernandez and Barreto in connection with the merger of RXMD with and into a wholly owned subsidiary of NextPlat (the “Merger”), which Merger was completed on October 1, 2024 following approval by the stockholders of each of NextPlat and RXMD in stockholder meetings held on September 13, 2024 by NextPlat and RXMD, respectively. Among other things, the complaint asserts that the consideration paid to Mr. Weisberg and the other RXMD stockholders in connection with the Merger was insufficient. The monetary relief requested in the complaint includes compensatory and rescissory damages in an unspecified dollar amount. The complaint is pending in the Court of Chancery of the State of Delaware. The caption is Alan Jay Weisberg v. Charles M. Fernandez, Rodney Barreto and NextPlat Corp., and the case number is C.A. No. 2024-1097-MTZ.
The Company believes the claims asserted in the action are without merit and intends to continue to vigorously defend against the lawsuit. The Company filed a motion to dismiss the complaint, which was denied by the court on December 3, 2025. Although the parties have engaged in discussions regarding a potential resolution of the matter, no agreement has been reached and there can be no assurance that the matter will be resolved on acceptable terms or at all. Oral argument on plaintiff's motion for class certification is scheduled for January 7, 2027. The parties have agreed to mediate the dispute. Based on currently available information and after consultation with legal counsel, management determined that a loss associated with this matter is probable and reasonably estimable in accordance with applicable accounting guidance. Accordingly, as of September 30, 2026, the Company has maintained an accrual of approximately $1.75 million, which represents management’s current estimate of loss exposure and corresponds to the Company’s applicable insurance retention under its directors’ and officers’ liability insurance coverage. The ultimate outcome of the matter remains uncertain, and the actual loss could differ materially from the amount accrued. Any such difference could have a material effect on the Company’s consolidated financial condition, results of operations, or cash flows in the period in which the matter is resolved.
From time to time, the Company may become involved in litigation relating to claims arising out of our operations in the normal course of business. Other than the matter described above, the Company is not currently involved in any pending legal proceeding or litigation, and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which the Company is a party or to which any of the Company’s properties is subject, which would reasonably be likely to have a material adverse effect on the Company’s business, financial condition and operating results.
ITEM 1A. RISK FACTORS
Investors should carefully consider the risks in the “Risk Factors” in Part 1: Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026, and our other filings with the SEC. These risks are not the only ones facing the Company. Additional risks not currently known to us or that we currently believe are immaterial may also impair our business operations. Any of these risks could adversely affect our business, cash flows, financial condition, and results of operations. The trading price of our common stock could fluctuate due to any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q. There have been no material changes in our risk factors from those discussed in our Annual Report on Form 10-K for the year ended December 31, 2025 other than as included below.
The suspension by Oscar Health of claims adjudication for our PharmcoRx subsidiary could adversely affect our revenue, results of operations and reputation, and could result in disputes or litigation whose outcome we cannot predict.
On October 30, 2026, PharmcoRx, our Florida pharmacy subsidiary, received written notice from CVS Caremark (“Caremark”), a pharmacy benefit manager, that Oscar Health (“Oscar”) had directed Caremark to place PharmcoRx on an adjudication suspension, effective immediately. The suspension covers all claims adjudicated to Oscar plans and will remain in effect until Oscar’s investigation is resolved or until further notice. The notice states that Oscar’s request was based on an allegation it described as indicative of fraud, waste or abuse, but it does not identify any specific claim or conduct by PharmcoRx. As of the date of this report, Oscar has not requested records from PharmcoRx or contacted PharmcoRx about the matter. The suspension applies only to claims adjudicated to Oscar plans at PharmcoRx’s Hallandale Beach, Florida location, and does not affect PharmcoRx’s other pharmacy locations. Caremark stated that it does not otherwise affect PharmcoRx’s participation in the Caremark network. Based on the information currently available to us, we believe the suspension relates to separate litigation brought by Oscar concerning alleged fraudulent activity involving certain 340B entities. PharmcoRx is not a party to that litigation.
Substantially all of PharmcoRx’s Oscar claims are dispensed as a contract pharmacy for 340B covered entities. For these claims, PharmcoRx earns a dispensing fee and remits the remaining reimbursement to the covered entity.
On November 4, 2026, counsel for PharmcoRx sent Oscar a letter asking Oscar to lift the suspension or, alternatively, to:
| ● |
disclose the specific basis for the suspension; |
| ● |
provide a process and timeline for PharmcoRx to demonstrate its compliance; and |
| ● |
confirm the payment status of PharmcoRx’s pre-suspension Oscar claims. |
PharmcoRx believes its Oscar claims were properly submitted. It offered to provide documentation about its dispensing to Oscar members and reserved its rights to pursue legal and regulatory remedies. Oscar did not respond by the requested date. As of the date of this report, PharmcoRx is evaluating its options, which may include a collaborative review with Oscar or legal action, including a request for injunctive relief.
While the suspension continues, PharmcoRx cannot earn dispensing fees on prescriptions for Oscar members. Oscar members may fill their prescriptions elsewhere, and some may not return even if the suspension is lifted. Covered entities whose patients are affected could also move their contract pharmacy arrangements to other pharmacies. Our contract pharmacy agreements can generally be terminated on 90 days’ notice. We cannot assure you that PharmcoRx's pre-suspension Oscar claims will be paid in full, or at all, or that Oscar or Caremark will not seek recoupment or other remedies. Our contract pharmacy agreements make the covered entities responsible for recoupments, less our dispensing fees. However, we could be required to fund recouped amounts before we recover them, and we bear the risk that a covered entity does not pay. We are aware that Oscar has communicated with certain patients about the suspension. Communications of this kind, together with the suspension itself, could damage PharmcoRx’s relationships and reputation with patients, prescribers and covered entities.
In addition, other payors, pharmacy benefit managers, covered entities or regulators may review PharmcoRx’s practices or take similar actions, whether because of the suspension, Oscar’s investigation or otherwise. Any such review or action could have a greater adverse effect on our business.
PharmcoRx intends to cooperate with Oscar and to continue working to minimize any disruption to patient care. However, it may have to pursue litigation or regulatory remedies to resolve the matter, and Oscar’s investigation could lead to claims or proceedings against PharmcoRx. Any dispute or proceeding could be costly and time-consuming and could divert management’s attention, and its outcome is uncertain. We cannot predict the duration or outcome of the suspension, Oscar’s investigation or any related proceedings, or their effect on our results of operations. If the suspension continues for an extended period, or is expanded or made permanent, our business, financial condition, results of operations and liquidity could be materially and adversely affected.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Amendment to Phipps Employment Agreement
On November 9, 2026, the Company and David Phipps, the Company’s Chief Executive Officer, entered into Amendment No. 2 (the “Amendment”) to the Employment Agreement between the Company and Mr. Phipps originally made effective as of August 11, 2024, as previously amended by Amendment No. 1 made effective September 24, 2025 (as amended, the “Agreement”). Pursuant to the Amendment, Section 4(a) of the Agreement was revised to increase Mr. Phipps’s base salary by $25,000, such that, effective as of November 9, 2026, his base salary is $475,000 per year. The Amendment further provides that the Company will continue to review Mr. Phipps’s base salary on an annual basis during the term of the Agreement and may increase, but not decrease, such salary. All other terms of the Agreement remain unchanged. The salary increase reflected in the Amendment was recommended by the Compensation Committee of the Company’s Board of Directors on October 14, 2026 and approved by the Board of Directors by unanimous written consent.
A copy of Amendment No. 2 to the Employment Agreement is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q and is incorporated herein by reference. The foregoing description of the Amendment is qualified in its entirety by reference to such exhibit.
Amendment to Ferrio Employment Agreement
On November 9, 2026, the Company and Amanda Ferrio, the Company’s Chief Financial Officer, entered into Amendment No. 1 to the Employment Agreement originally made effective as of January 9, 2026 (the “Agreement”). Pursuant to the Amendment, Section 4(a) of the Agreement was revised to increase Ms. Ferrio’s base salary by $15,000, such that, effective as of November 9, 2026, her base salary is $240,000 per year, payable in bi-weekly installments in accordance with the Company’s normal payroll practices, subject to applicable withholding. The Amendment provides that the Company will continue to review Ms. Ferrio’s base salary on an annual basis during the term of the Agreement and may increase, but not decrease, such salary. The salary increase reflected in the Amendment was recommended by the Compensation Committee of the Company’s Board of Directors on October 14, 2026 and approved by the Board of Directors by unanimous written consent.
A copy of Amendment No. 1 to the Employment Agreement is filed as Exhibit 10.3 to this Quarterly Report on Form 10-Q and is incorporated herein by reference. The foregoing description of the Amendment is qualified in its entirety by reference to such exhibit.
Rule 10b5-1 Trading Arrangement
During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
ITEM 6. EXHIBITS
| Exhibit Number | Description | |||
| 10.1 | Membership Interest Purchase Agreement, dated as of July 14, 2026 by and between Ron G. Scott and Progressive Care LLC (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 16, 2026). | |||
| 10.2 | Amendment No. 2 to Employment Agreement by and between NextPlat Corp and David Phipps dated as of November 9, 2026. | |||
| 10.3 | Amendment No. 1 to Employment Agreement by and between NextPlat Corp and Amanda Ferrio dated as of November 9, 2026. | |||
| 31.1 |
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|||
| 31.2 |
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|||
| 32.1 |
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|||
| 101.INS |
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its Inline XBRL tags are embedded within the Inline XBRL document. |
|||
| 101 | The following condensed consolidated financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in Inline XBRL: (i) Condensed Consolidated Statements of Comprehensive Loss, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Changes in Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags. | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: November 16, 2026 |
NEXTPLAT CORP |
|
| By: |
/s/ David Phipps |
|
| David Phipps |
||
| Chief Executive Officer and President |
||
| (Principal Executive Officer) |
||
| /s/ Amanda Ferrio |
||
| Amanda Ferrio | ||
| Chief Financial Officer |
||
| (Principal Financial and Accounting Officer) |
||